Gan L, Shen JF, Yao MX, Chen ZG, Zhuang ZX. Kirsten rat sarcoma G12C inhibitor treatment for a patient with relapsed metastatic lung adenocarcinoma: A case report. World J Clin Cases 2025; 13(31): 108942 [DOI: 10.12998/wjcc.v13.i31.108942]
Corresponding Author of This Article
Lei Gan, PhD, Department of Oncology, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Gusu District, Suzhou 215004, Jiangsu Province, China. ganlei19870810@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nov 6, 2025 (publication date) through Nov 8, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Gan L, Shen JF, Yao MX, Chen ZG, Zhuang ZX. Kirsten rat sarcoma G12C inhibitor treatment for a patient with relapsed metastatic lung adenocarcinoma: A case report. World J Clin Cases 2025; 13(31): 108942 [DOI: 10.12998/wjcc.v13.i31.108942]
Kirsten rat sarcoma G12C inhibitor treatment for a patient with relapsed metastatic lung adenocarcinoma: A case report
Lei Gan, Jiao-Feng Shen, Meng-Xian Yao, Zhi-Gang Chen, Zhi-Xiang Zhuang
Lei Gan, Jiao-Feng Shen, Meng-Xian Yao, Zhi-Gang Chen, Zhi-Xiang Zhuang, Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu Province, China
Author contributions: Gan L, Shen JF, Yao MX, Chen ZG, and Zhuang ZX wrote the initial draft of the manuscript; Shen JF, Yao MX, Chen ZG, and Zhuang ZX contributed to data analysis, revising and reviewing the manuscript. All authors have approved the final version and accept responsibility for the entire work, including addressing any concerns regarding its accuracy or integrity.
Supported by National Natural Sciences Foundation of China, No. 81803553.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lei Gan, PhD, Department of Oncology, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Gusu District, Suzhou 215004, Jiangsu Province, China. ganlei19870810@163.com
Received: May 7, 2025 Revised: May 31, 2025 Accepted: September 8, 2025 Published online: November 6, 2025 Processing time: 182 Days and 19.6 Hours
Core Tip
Core Tip: Non-small cell lung cancer represents 85% of all pulmonary malignancies globally. Kirsten rat sarcoma viral oncogene homolog (KRAS) is among the most common mutations observed in malignant tumors, with roughly 13% of pulmonary adenocarcinomas carrying the KRAS at glycine 12 to cysteine (G12C) mutation. In this case, the initial therapeutic strategies for KRAS G12C-mutant lung adenocarcinomas were similar to those for driver mutation-negative non-small cell lung cancer. Following relapse, with KRAS G12C inhibitor administration, the patient’s post-relapse progression-free survival reached 17 months. Subsequently, the patient’s disease progressed, necessitating renewed treatment with radiotherapy, chemotherapy, and targeted therapy.
